LIANBIO-ADR (LIAN) Stock Price, Quote, News and Overview
NASDAQ:LIAN - Nasdaq - US53000N1081 - ADR - Currency: USD
LIAN Quote, Performance and Key Statistics
0.319
-0.03 (-8.28%)
The current stock price of LIAN is 0.319 USD. In the past month the price decreased by -93.31%. In the past year, price decreased by -80.9%.
LIAN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About LIAN
Company Profile
LianBio operates as a biopharmaceutical company, which engages in the development and commercialization of medicines for patients with unmet medical needs. The company is headquartered in Princeton, New Jersey and currently employs 163 full-time employees. The company went IPO on 2021-10-28. The firm is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. The company has a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications. Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX-13 and LYR-210. Mavacamten is an oral small-molecule allosteric modulator of cardiac myosin, which is approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and is also being studied as a treatment for other diseases of diastolic dysfunction. TP-03 is a topical ophthalmic formulation of lotilaner, that is used for the treatment of demodex blepharitis (DB) and meibomian gland disease (MGD). NBTXR3 is a radio enhancer for the treatment of head and neck cancer and other solid tumors.
Company Info
LIANBIO-ADR
103 Carnegie Center Drive, Suite 309, Suite 215
Princeton NEW JERSEY US
Employees: 163
Company Website: https://www.lianbio.com/
Phone: 16094862308
LIANBIO-ADR / LIAN FAQ
What is the stock price of LIANBIO-ADR today?
The current stock price of LIAN is 0.319 USD. The price decreased by -8.28% in the last trading session.
What is the ticker symbol for LIANBIO-ADR stock?
The exchange symbol of LIANBIO-ADR is LIAN and it is listed on the Nasdaq exchange.
On which exchange is LIAN stock listed?
LIAN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LIANBIO-ADR stock?
6 analysts have analysed LIAN and the average price target is 3.98 USD. This implies a price increase of 1147.02% is expected in the next year compared to the current price of 0.319. Check the LIANBIO-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LIANBIO-ADR worth?
LIANBIO-ADR (LIAN) has a market capitalization of 34.47M USD. This makes LIAN a Nano Cap stock.
How many employees does LIANBIO-ADR have?
LIANBIO-ADR (LIAN) currently has 163 employees.
Is LIANBIO-ADR (LIAN) expected to grow?
The Revenue of LIANBIO-ADR (LIAN) is expected to decline by -100% in the next year. Check the estimates tab for more information on the LIAN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy LIANBIO-ADR (LIAN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LIAN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LIAN, evaluating the profitability, health, valuation and growth aspects
- LIANBIO-ADR (LIAN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LIANBIO-ADR (LIAN) Sales and EPS estimates to see what analysts future expectations are.
- LIANBIO-ADR (LIAN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LIANBIO-ADR (LIAN) Insider and Institutional Ownership to learn about the owners and their transactions.
- LIANBIO-ADR (LIAN) Stock Chart to make your own analysis
- LIANBIO-ADR (LIAN) Latest news and press-releases to stay up to date.
Does LIANBIO-ADR (LIAN) stock pay dividends?
LIAN does not pay a dividend.
When does LIANBIO-ADR (LIAN) report earnings?
LIANBIO-ADR (LIAN) will report earnings on 2024-05-09, after the market close.
What is the Price/Earnings (PE) ratio of LIANBIO-ADR (LIAN)?
LIANBIO-ADR (LIAN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.81).
LIAN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to LIAN. When comparing the yearly performance of all stocks, LIAN is a bad performer in the overall market: 99.75% of all stocks are doing better.
LIAN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LIAN. LIAN has a great financial health rating, but its profitability evaluates not so good.
LIAN Financial Highlights
Over the last trailing twelve months LIAN reported a non-GAAP Earnings per Share(EPS) of -0.81. The EPS increased by 28.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.47% | ||
| ROE | -43.49% | ||
| Debt/Equity | 0 |
LIAN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to LIAN. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 16% and a revenue growth -100% for LIAN